Sonam Dodhia1, Katrina Celis2, Alana Aylward3, Yi Cai1, Maria E Fontana4, Alberto Trespalacios5, David C Hoffman6, Henry Ostos Alfonso7, Sidney B Eisig8, Gloria H Su1,9, Wendy K Chung10,11, Joseph Haddad1. 1. Department of Otolaryngology-Head and Neck Surgery, Columbia University Medical Center, New York, New York, U.S.A. 2. John P. Hussman Institute for Genomics, University of Miami, Miami, Florida, U.S.A. 3. Department of Otolaryngology-Head and Neck Surgery, University of Utah, Salt Lake City, Utah, U.S.A. 4. College of Dental Medicine, Columbia University, New York, New York, U.S.A. 5. Department of Plastic Surgery, Hernando Moncaleano University Hospital, Neiva, Huila, Colombia. 6. Department of Oral and Maxillofacial Surgery, Staten Island University Hospital, Staten Island, New York, U.S.A. 7. Laboratory of Genomic Medicine, South Colombian University, Neiva, Huila, Colombia. 8. Department of Craniofacial Surgery, Columbia University Medical Center, New York, New York, U.S.A. 9. Pathology and Cell Biology, Columbia University Medical Center, New York, New York, U.S.A. 10. Pediatrics, Columbia University Medical Center, New York, New York, U.S.A. 11. Medicine, Columbia University Medical Center, New York, New York, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: A candidate variant (p.Val496Ala) of the ACSS2 gene (T > C missense, rs59088485 variant at chr20: bp37 33509608) was previously found to consistently segregate with nonsyndromic cleft lip and/or palate (NSCLP) in three Honduran families. Objectives of this study were 1) to investigate the frequency of this ACSS2 variant in Honduran unrelated NSCLP patients and unrelated unaffected controls and 2) to investigate the frequency of this variant in Colombian unrelated affected NSCLP patients and unrelated unaffected controls. STUDY DESIGN: Case-control studies. METHODS: Sanger sequencing of 99 unrelated Honduran NSCLP patients and 215 unrelated unaffected controls for the p.Val496Ala ACSS2 variant was used to determine the carrier frequency in NSCLP patients and controls. Sanger sequencing of 230 unrelated Colombian NSCLP patients and 146 unrelated unaffected controls for the p.Val496Ala ACSS2 variant was used to determine the carrier frequency in NSCLP patients and controls. RESULTS: In the Honduran population, the odds ratio of having NSCLP among carriers of the p.Val496Ala ACSS2 variant was 4.0 (P = .03), with a carrier frequency of seven of 99 (7.1%) in unrelated affected and four of 215 (1.9%) in unrelated unaffected individuals. In the Colombian population, the odds ratio of having NSCLP among carriers of the p.Val496Ala ACSS2 variant was 2.6 (P = .04), with a carrier frequency of 23 of 230 (10.0%) in unrelated affected and six of 146 (4.1%) in unrelated unaffected individuals. CONCLUSIONS: These findings support the role of ACSS2 in NSCLP in two independent Hispanic populations from Honduras and Colombia. LEVEL OF EVIDENCE: NA Laryngoscope, 127:E336-E339, 2017.
OBJECTIVES/HYPOTHESIS: A candidate variant (p.Val496Ala) of the ACSS2 gene (T > C missense, rs59088485 variant at chr20: bp37 33509608) was previously found to consistently segregate with nonsyndromic cleft lip and/or palate (NSCLP) in three Honduran families. Objectives of this study were 1) to investigate the frequency of this ACSS2 variant in Honduran unrelated NSCLP patients and unrelated unaffected controls and 2) to investigate the frequency of this variant in Colombian unrelated affected NSCLP patients and unrelated unaffected controls. STUDY DESIGN: Case-control studies. METHODS: Sanger sequencing of 99 unrelated Honduran NSCLP patients and 215 unrelated unaffected controls for the p.Val496AlaACSS2 variant was used to determine the carrier frequency in NSCLP patients and controls. Sanger sequencing of 230 unrelated Colombian NSCLP patients and 146 unrelated unaffected controls for the p.Val496AlaACSS2 variant was used to determine the carrier frequency in NSCLP patients and controls. RESULTS: In the Honduran population, the odds ratio of having NSCLP among carriers of the p.Val496AlaACSS2 variant was 4.0 (P = .03), with a carrier frequency of seven of 99 (7.1%) in unrelated affected and four of 215 (1.9%) in unrelated unaffected individuals. In the Colombian population, the odds ratio of having NSCLP among carriers of the p.Val496AlaACSS2 variant was 2.6 (P = .04), with a carrier frequency of 23 of 230 (10.0%) in unrelated affected and six of 146 (4.1%) in unrelated unaffected individuals. CONCLUSIONS: These findings support the role of ACSS2 in NSCLP in two independent Hispanic populations from Honduras and Colombia. LEVEL OF EVIDENCE: NA Laryngoscope, 127:E336-E339, 2017.
Authors: Lusine Aghajanova; Shehua Shen; Angela M Rojas; Susan J Fisher; Juan C Irwin; Linda C Giudice Journal: Biol Reprod Date: 2012-01-16 Impact factor: 4.285
Authors: Augusto Rojas-Martinez; Heiko Reutter; Oscar Chacon-Camacho; Rafael B R Leon-Cachon; Sergio G Munoz-Jimenez; Stefanie Nowak; Jessica Becker; Ruth Herberz; Kerstin U Ludwig; Mario Paredes-Zenteno; Abelardo Arizpe-Cantú; Susanne Raeder; Stefan Herms; Rocio Ortiz-Lopez; Michael Knapp; Per Hoffmann; Markus M Nöthen; Elisabeth Mangold Journal: Birth Defects Res A Clin Mol Teratol Date: 2010-07
Authors: Sarah A Comerford; Zhiguang Huang; Xinlin Du; Yun Wang; Ling Cai; Agnes K Witkiewicz; Holly Walters; Mohammed N Tantawy; Allie Fu; H Charles Manning; Jay D Horton; Robert E Hammer; Steven L McKnight; Benjamin P Tu Journal: Cell Date: 2014-12-18 Impact factor: 41.582
Authors: Zachary T Schug; Barrie Peck; Dylan T Jones; Qifeng Zhang; Shaun Grosskurth; Israt S Alam; Louise M Goodwin; Elizabeth Smethurst; Susan Mason; Karen Blyth; Lynn McGarry; Daniel James; Emma Shanks; Gabriela Kalna; Rebecca E Saunders; Ming Jiang; Michael Howell; Francois Lassailly; May Zaw Thin; Bradley Spencer-Dene; Gordon Stamp; Niels J F van den Broek; Gillian Mackay; Vinay Bulusu; Jurre J Kamphorst; Saverio Tardito; David Strachan; Adrian L Harris; Eric O Aboagye; Susan E Critchlow; Michael J O Wakelam; Almut Schulze; Eyal Gottlieb Journal: Cancer Cell Date: 2015-01-12 Impact factor: 31.743
Authors: Andrés Moreno-Estrada; Simon Gravel; Fouad Zakharia; Jacob L McCauley; Jake K Byrnes; Christopher R Gignoux; Patricia A Ortiz-Tello; Ricardo J Martínez; Dale J Hedges; Richard W Morris; Celeste Eng; Karla Sandoval; Suehelay Acevedo-Acevedo; Paul J Norman; Zulay Layrisse; Peter Parham; Juan Carlos Martínez-Cruzado; Esteban González Burchard; Michael L Cuccaro; Eden R Martin; Carlos D Bustamante Journal: PLoS Genet Date: 2013-11-14 Impact factor: 5.917